

In a second aspect of the present application, there is provided a use of a compound in the manufacture of a medicament for treating ocular diseases, wherein said medicament is to be administered in a sustained release intraocular drug delivery device as defined herein, and wherein said sustained release intraocular drug delivery device is to be inserted into the sulcus of the eye, such that the ocular disease is treated, wherein said compound is selected from the group consisting of: bevacizumab, ranibizumab, aflibercept, timolol, latanoprost, dorzolamide, triamcinolone, dexamethasone and cyclosporine.

A third aspect of the present application provides a process when used to prepare a sustained release intraocular drug delivery device according to the first aspect of the present application, which comprises:

- mixing the at least one therapeutic agent with an insoluble and inert polymer disclosed herein;
- molding and/ or extruding said mixture to afford a polymeric matrix core; and,
- providing the resulting polymeric matrix core with a polymeric coating disclosed herein.

The present disclosure hence provides for a method of manufacturing an intraocular drug delivery device according to the present disclosure for use in treating eye-related disorders.

A fourth aspect of the present disclosure provides a use of a compound in the manufacture of a medicament for treating ocular diseases, wherein said medicament is to be administered in a device as defined herein, and wherein said device is to be inserted or implanted into the sulcus of the eye by a surgical method, wherein the device is to be partially straightened by applying force, the device is to be inserted in the sulcus of the eye, and the device is to be released, wherein said compound is selected from the group consisting of: bevacizumab, ranibizumab, aflibercept, timolol, latanoprost, dorzolamide, triamcinolone, dexamethasone and cyclosporine.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A, shows a three-dimensional representation of the polymeric matrix of the intraocular drug delivery device, according to an embodiment of the present application. **Figure 1B**, shows a side view of the polymeric matrix of the intraocular drug delivery device, according to an embodiment of the present application.

Figure 2A, shows a three-dimensional representation of the sustained release intraocular drug delivery device, according to an embodiment of the present application. **Figure 2B**, shows a side view of the polymeric matrix of the sustained release intraocular drug delivery device, according to an embodiment of the present application.

Figure 3 shows a calibration curve of timolol.

Figure 4 shows a calibration curve of dorzolamide.

- providing the resulting polymeric matrix core with a polymeric coating of claim 8.

18. The process of claim 17, wherein the step of providing the resulting polymer matrix core with a polymeric coating is performed by covering said resulting polymeric matrix core with a polymeric membrane in a mold, and heating said mold.

- 5 19. The process according to claim 17 or 18, when used to manufacture an intraocular device for insertion in the sulcus of the eye, for the treatment of ocular diseases.

20. Use of a compound in the manufacture of a medicament for treating ocular diseases, wherein said medicament is to be administered in a device according to claims 1 to 15, and wherein said device is to be inserted or implanted into the sulcus of the eye by a surgical
10 method, wherein the device is to be partially straightened by applying force, the device is to be inserted in the sulcus of the eye, and the device is to be released, wherein said compound is selected from the group consisting of: bevacizumab, ranibizumab, aflibercept, timolol, latanoprost, dorzolamide, triamcinolone, dexamethasone and cyclosporine.